Acorda Therapeutics (ACOR) Tops Q1 EPS by 18c

Acorda Therapeutics (NASDAQ: ACOR) reported Q1 EPS of $0.36, $0.18 better than the analyst estimate of $0.18. Revenue for the quarter came in at $71.25 million versus the consensus estimate of $70.95 million.

For earnings history and earnings-related data on Acorda Therapeutics (ACOR) click here.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Diana Shipping drops bid for Genco after price demands spike to $36.91
• Cisco rating cut at HSBC as analyst sees a lack of catalysts